Amicus Therapeutics to Acquire Rare Disease Company Scioderm, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Cowen Raises Price Target on Amicus Therapeutics (FOLD) Following Announced Deal for Scioderm
September 1, 2015 7:10 AM EDTCowen reiterated an Outperform rating on Amicus Therapeutics (NASDAQ: FOLD), and raised the price target to $27.00 (from $19.00), following the announced cash/stock deal for Scioderm. Scioderms Zorblisa is in a Ph3 trial for the rare skin disease Epidermolysis Bullosa (EB) with FDA Breakthrough... More
Leerink Partners Remains Bullish on Amicus Therapeutics (FOLD) Following Announced Scioderm Acquisition
August 31, 2015 2:00 PM EDTLeerink Partners reiterated an Outperform rating on Amicus Therapeutics (NASDAQ: FOLD) following the announced acquisition of Scioderm. Scioderm is a private company developing Zorblisa (SD-101), its lead product for epidermolysis bullosa that is currently enrolling for Phase 3 trial. Data readout is expected by 1H16.... More
Amicus Therapeutics (FOLD) to Acquire Scioderm in ~$950M Deal
August 31, 2015 6:29 AM EDTAmicus Therapeutics (NASDAQ: FOLD) and Scioderm, Inc. a privately-held biopharmaceutical company focused on developing innovative therapies for treating diseases with high unmet need, have signed a definitive agreement under which Amicus will acquire 100% of the capital stock of Scioderm, Inc.
Transaction highlights
Excellent strategic fit with Amicus' patient-centric vision to develop and commercialize advanced therapies for devastating rare and orphan diseasesLeverages Scioderm development team's EB expertise with Amicus' global clinical infrastructure to advance Zorblisa toward regulatory approvals and Amicus' commercial, patient advocacy and medical affairs infrastructure to support a successful global... More